Paralysis Reversed by Neuromuscular-blocking antagonist the Monitoring of Recurrent Laryngeal Nerve in Thyroid Carcinoma Surgery, Single Center, Randomized, Controlled Clinical Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015797

Enrollment

Unknown

Registered

2018-04-20

Start date

2018-05-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Carcinoma

Interventions

1:Rocuronium 0.6mg / kg+ neostigmine 50 g/kg

2:Rocuronium 0.6mg / kg

3:Rocuronium 0.6mg / kg+ neostigmine 25 g/kg

4:Rocuronium 0.6mg / kg+ neostigmine 50 g/kg

5:Rocuronium 0.6mg / kg+ neostigmine 100 g/kg

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years male and female; 2. ASA grade I or II; 3. body mass index (BMI) <30kg/m2; 4. Thyroid cancer patients; 5. Voluntarily participated in and signed a letter of informed consent.

Exclusion criteria

Exclusion criteria: 1. is known to be allergic to the main drug or any excipient in this product; 2. patients did not agree to receive recurrent laryngeal nerve monitoring; 3. patients receiving medication for neuromuscular blocking agents; 4. elevated intracranial pressure or head injury; 5. patients with hypotension, asthma (avoid seizure), epilepsy, neuropathy or neuromuscular diseases; 6. patients who predict difficult airway; 7. the function of liver and kidney before operation: alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN), and creatinine (Cr) abnormality (ALT and AST are 1.5 times higher than the upper limit of normal value, BUN and Cr are higher than the upper limit of normal value); 8. coronary heart disease, bronchial asthma, poorly controlled or difficult to control hypertension: systolic blood pressure (SBP) over 160mmHg or diastolic blood pressure (DBP) greater than 100mmHg; 9. respiratory insufficiency, respiratory failure; 10. patients who are not able to express their intentions correctly are not able to follow the research plan; 11. other drug trials in 30 days before admission; 12. abnormal coagulation function; 13. researchers believe those who is not suitable to participate in the study.

Design outcomes

Primary

Measure	Time frame
TOFr;EMGr;	—

Countries

China

Contacts

Public ContactMiao Changhong

Fudan University Shanghai Cancer Center

miaochh@aliyun.com+86 13681975062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026